Bluejay Diagnostics Inc Market Cap ($1.78 Million)
Market Cap & Net Worth: Bluejay Diagnostics Inc (BJDX)
Bluejay Diagnostics Inc market cap. Bluejay Diagnostics Inc (NASDAQ:BJDX) has a market capitalization of $1.78 Million ($1.78 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30153 globally and #6151 in its home market, demonstrating a 294.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bluejay Diagnostics Inc's stock price $2.21 by its total outstanding shares 1034715 (1.03 Million). Also see BJDX cash flow conversion for how efficiently the company converts equity into cash flow.
Bluejay Diagnostics Inc Market Cap History (2021–2026)
Bluejay Diagnostics Inc market cap history from 2021 to 2026. Data shows change from $21.19 Billion to $2.29 Million (-86.19% CAGR). Check Bluejay Diagnostics Inc share price for real-time trading data and today's change.
Index Memberships
Bluejay Diagnostics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #876 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2791 of 3165 |
Weight: Bluejay Diagnostics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bluejay Diagnostics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bluejay Diagnostics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Bluejay Diagnostics Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
12630.64x
Bluejay Diagnostics Inc's market cap is 12630.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $21.19 Billion | $75.00 | -$3.73 Million | 282546176.00x | N/A |
| 2022 | $3.15 Billion | $249.04K | -$9.30 Million | 12630.64x | N/A |
Competitor Companies of BJDX by Market Capitalization
Companies near Bluejay Diagnostics Inc in the global market cap rankings as of November 4, 2026. Also see BJDX current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Bluejay Diagnostics Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $190.23 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $119.12 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #226 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $190.23 Billion | $109.40 |
| #204 | Stryker Corporation | NYSE:SYK | $119.12 Billion | $310.55 |
| #226 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $98.88 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Bluejay Diagnostics Inc (2021–2026)
Market capitalization of Bluejay Diagnostics Inc from 2021 to today. Between 2021 and today, Bluejay Diagnostics Inc's market cap moved from $21.19 Billion to $ 2.29 Million, with a yearly change of -86.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.29 Million | +231.24% |
| 2025 | $690.36K | -86.30% |
| 2024 | $5.04 Million | -99.00% |
| 2023 | $504.94 Million | -83.95% |
| 2022 | $3.15 Billion | -85.16% |
| 2021 | $21.19 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Bluejay Diagnostics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.78 Million USD |
| MoneyControl | $1.78 Million USD |
| MarketWatch | $1.78 Million USD |
| marketcap.company | $1.78 Million USD |
| Reuters | $1.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoas… Read more